This article has Open Peer Review reports available.
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
© The Author(s). 2016
Received: 25 October 2015
Accepted: 12 July 2016
Published: 26 July 2016
Open Peer Review reports
Pre-publication versions of this article are available by contacting email@example.com.
|25 Oct 2015||Submitted||Original manuscript|
|4 Feb 2016||Reviewed||Reviewer Report - Lekha Pandit|
|10 Feb 2016||Reviewed||Reviewer Report - Vijayshree Yadav|
|3 Mar 2016||Reviewed||Reviewer Report - Daniel M Harrison|
|15 Apr 2016||Author responded||Author comments - Ralf Gold|
|Resubmission - Version 2|
|15 Apr 2016||Submitted||Manuscript version 2|
|22 Jun 2016||Author responded||Author comments - Ralf Gold|
|Resubmission - Version 3|
|22 Jun 2016||Submitted||Manuscript version 3|
|12 Jul 2016||Editorially accepted|
|26 Jul 2016||Article published||10.1186/s12883-016-0635-y|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.